Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
LRMR
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-0.19
vs -0.47
Q3.23
N/A
-0.21
vs -0.37
Q4.23
N/A
-0.30
vs -0.21
Q1.24
N/A
-0.27
vs -0.15
Q2.24
N/A
-0.34
vs -0.19
Q3.24
N/A
-0.24
vs -0.21
Q4.24
N/A
-0.45
vs -0.30
Q1.25
N/A
-0.46
vs -0.27
Q2.25
N/A
-0.48
vs -0.34
Q3.25
N/A
-0.49
vs -0.24
Sales Growth
YoY
Current
Estimates
Q4.22
NA
NA vs NA
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
NA vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
NA
241K vs NA
Q1.25
NA
NA vs NA
Return on Equity
QoQ
Q2.23
-8%
-0.08
vs -0.05
Q3.23
-10%
-0.10
vs -0.08
Q4.23
-16%
-0.16
vs -0.10
Q1.24
-6%
-0.06
vs -0.16
Q2.24
-10%
-0.10
vs -0.06
Q3.24
-8%
-0.08
vs -0.10
Q4.24
-17%
-0.17
vs -0.08
Q1.25
-20%
-0.20
vs -0.17
Institutionnal Ownership
QoQ
Q2.23
67
67
vs 69
-3%
Q3.23
67
67
vs 67
NA
Q4.23
74
74
vs 67
10%
Q1.24
112
112
vs 74
51%
Q2.24
110
110
vs 112
-2%
Q3.24
127
127
vs 110
15%
Q4.24
123
123
vs 127
-3%
Q1.25
105
105
vs 123
-15%
globenewswire.com
7 hours ago
benzinga.com
13 hours ago
globenewswire.com
16 hours ago
seekingalpha.com
17 hours ago
Quote Panel
Key Metrics
Forecast
NaN%2026-Revenue
-328%2026-EPS
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
Oppenheimer
initialisePrevious: Not converted
2024-10-15
Now: Outperform
Wedbush
initialisePrevious: Not converted
2024-10-03
Now: Outperform
H.C. Wainwright
initialisePrevious: Not converted
2024-10-02
Now: Buy
Citigroup
initialisePrevious: Not converted
2022-12-13
Now: Neutral
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
NASDAQ
Unprofitable
Unprofitable
-0.12Â ( -4.15%)
Relative Strenght
19
Volume Buzz
-67%
Earning Acce
No
Dist 52w H.
75%Relative Strength
LRMR
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|